These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23763704)

  • 41. A liquid thromboplastin reagent for the determination of PT.
    Butler J; Torres J; Callahan J
    Am Clin Lab; 1994 Mar; 13(3):16-7. PubMed ID: 10147376
    [No Abstract]   [Full Text] [Related]  

  • 42. Thioester chromogenic substrates for human factor VIIa: substituted isocoumarins are inhibitors of factor VIIa and in vitro anticoagulants.
    Kam CM; Vlasuk GP; Smith DE; Arcuri KE; Powers JC
    Thromb Haemost; 1990 Aug; 64(1):133-7. PubMed ID: 2274918
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison between the dilution curves of prothrombin time and activated partial thromboplastin time for the control of the effect of anti-vitamin K].
    Langer B; Fuess VL; Kauffman P; Bechara MJ; dos Reis JM; Kwang WT
    Rev Hosp Clin Fac Med Sao Paulo; 1984; 39(1):18-22. PubMed ID: 6385200
    [No Abstract]   [Full Text] [Related]  

  • 44. Criteria for an acceptable thromboplastin preparation.
    Owren PA
    Thromb Diath Haemorrh; 1975 Apr; 33(2):165-71. PubMed ID: 49085
    [No Abstract]   [Full Text] [Related]  

  • 45. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
    Gerotziafas GT; Baccouche H; Sassi M; Galea V; Chaari M; Hatmi M; Samama MM; Elalamy I
    Thromb Res; 2012 Jan; 129(1):101-3. PubMed ID: 22000405
    [No Abstract]   [Full Text] [Related]  

  • 46. Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies.
    Arrants J; Willis ME; Stevens B; Gripkey L; Herman JA; Hernandez-Brooks L; Eaker JE
    Am J Crit Care; 1999 Sep; 8(5):344-8. PubMed ID: 10467472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
    Harenberg J; Marx S; Krämer R; Giese C; Weiss C
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer.
    Rose VL; Dermott SC; Murray BF; McIver MM; High KA; Oberhardt BJ
    Arch Pathol Lab Med; 1993 Jun; 117(6):611-7. PubMed ID: 8503733
    [TBL] [Abstract][Full Text] [Related]  

  • 49. One-stage prothrombin time survey.
    Zucker S; Brosious E; Cooper GR
    Am J Clin Pathol; 1970 Mar; 53(3):340-7. PubMed ID: 5416771
    [No Abstract]   [Full Text] [Related]  

  • 50. Usefulness of high-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value.
    Kanahara M; Kai H; Okamura T; Wada T; Suda K; Imaizumi T; Sagawa K
    Thromb Res; 2008; 121(6):781-5. PubMed ID: 17904620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control.
    Thromb Haemost; 1985 Feb; 53(1):155-6. PubMed ID: 3992515
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparability of the results of PT-INR with local MNPT and APTTR with MNAPTT on different coagulation analyzers in China.
    Peng L; Yan C; Wu X; Nie L
    Int J Lab Hematol; 2009 Jun; 31(3):352-8. PubMed ID: 18510575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of telavancin on coagulation test results.
    Barriere SL; Goldberg MR; Janc JW; Higgins DL; Macy PA; Adcock DM
    Int J Clin Pract; 2011 Jul; 65(7):784-9. PubMed ID: 21564449
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer.
    Shirts BH; Rodgers GM; Smock KJ
    Thromb Res; 2012 Sep; 130(3):e134-8. PubMed ID: 22542363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progress in the control of oral anticoagulation.
    Loeliger EA
    Thromb Diath Haemorrh; 1972 Aug; 28(1):109-19. PubMed ID: 5074987
    [No Abstract]   [Full Text] [Related]  

  • 56. Oral anticoagulants.
    Winter JH; Douglas AS
    Clin Haematol; 1981 Jun; 10(2):459-80. PubMed ID: 7032784
    [No Abstract]   [Full Text] [Related]  

  • 57. Quality control in coagulation studies. An evaluation of control systems for plasma prothrombin determination.
    Bowerman D; Notestine H
    Tech Bull Regist Med Technol; 1969 Mar; 39(3):67-9. PubMed ID: 5775265
    [No Abstract]   [Full Text] [Related]  

  • 58. The interpretation of prothrombin results: a national survey.
    Poller L; Thomson JM
    Br J Haematol; 1969; 16(1):31-7. PubMed ID: 5795212
    [No Abstract]   [Full Text] [Related]  

  • 59. A comparative study of three methods measuring prothrombin time.
    Gudaitis AV; Donauer RM
    Clin Chem; 1968 Sep; 14(9):911-7. PubMed ID: 5675313
    [No Abstract]   [Full Text] [Related]  

  • 60. Italian guidelines for the appropriate use of plasma.
    Marconi M
    Tumori; 2001; 87(2):S14-6. PubMed ID: 11401216
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.